CryoPort, Inc. (CYRX) News
Filter CYRX News Items
CYRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CYRX News From Around the Web
Below are the latest news stories about CRYOPORT INC that investors may wish to consider to help them evaluate CYRX as an investment opportunity.
Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain ServicesCryoport Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, and NIPPON EXPRESS HOLDINGS, INC. ("Nippon Express"), global logistics company, today announced a strategic partnership to provide temperature-controlled supply chain services for the life sciences industry on a global basis. |
Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird ExpressCryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced the expansion of its global supply chain network with the acquisition of Bluebird Express, LLC ("Bluebird Express"), a provider of time-sensitive domestic and international transportation services. Bluebird Express will join Cryoport's CRYOPDP bu |
At US$11.25, Is It Time To Put Cryoport, Inc. (NASDAQ:CYRX) On Your Watch List?Cryoport, Inc. ( NASDAQ:CYRX ), is not the largest company out there, but it saw a significant share price rise of over... |
Cryoport, Inc. (NASDAQ:CYRX) Q3 2023 Earnings Call TranscriptCryoport, Inc. (NASDAQ:CYRX) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good afternoon and welcome to Cryoport Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I will now turn the call over to your host, Todd Fromer from KCSA Strategic Communications. Please go ahead. Todd Fromer: […] |
CryoPort Inc (CYRX) Faces Economic Headwinds but Sees Growth in Key SegmentsQ3 2023 Earnings Report Summary |
Cryoport Reports Third Quarter 2023 Financial ResultsCryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the life sciences, with a focus on the fast-growing cell and gene therapy industry, enabling the future of medicine for a new era of life sciences, today announced financial results for the third quarter (Q3) and first nine months (9M) of 2023. |
Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH AcquisitionCryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced the acquisition of Tec4med Lifescience GmbH ("Tec4med"), a solution provider and innovation leader in the pharmaceutical supply chain visibility, condition monitoring and temperature-controlled packaging space. |
Analysts Estimate CryoPort, Inc. (CYRX) to Report a Decline in Earnings: What to Look Out forCryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 after U.S. markets close. |
Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVFCryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, today announced that the Company has signed a new three-year supply chain solutions agreement with Monash IVF Group Limited (ASX: MVF), a leading provider of assisted reproductive services, as well as specialist women's imaging and diagnostic services in Austral |